ImmunityBio Inc. (NASDAQ:IBRX) is one of the 13 Stocks Under $5 With High Upside Potential. ImmunityBio Inc. (NASDAQ:IBRX) ...

BACKGROUND: It is unknown if incidental lymphopenia detected in the general population is associated with higher all-cause and cause-specific mortality. We aimed to identify the associations between ...

ImmunityBio, Inc. today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a ...

Treatment-induced lymphopenia can be a consequence of radiation therapy, chemotherapy and certain immunotherapies, as well as steroids. Anktiva is designed specifically to address Bacille Calmette ...

Similarly, lymphopenia is associated with increased risk for pneumonia mortality in persons living with HIV/AIDS. The Hamilton study is unique in that it focuses on a broad primary care population.

The lymphopenia opportunity provides an attractive valuation, even when risk-adjusted. The FDA's recent compassionate use authorisation could draw more attention to this area of treatment, which ...

Recent reports have shown that marked lymphopenia is observed in 83.2% of SARS-CoV-2 patients, but little is known about how SARS-CoV-2 effectively dismantles one of our primary tools of defense.

Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic cancer.

CULVER CITY, Calif., June 03, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy.